---
title: "Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252618888.md"
description: "Jiuzhou Pharma's subsidiary, Reibo Suzhou, underwent a cGMP on-site inspection by the U.S. FDA from May 19 to 22, 2025, and passed the inspection. This inspection covered six major systems, including quality systems, materials, and production, indicating that Reibo Suzhou meets FDA requirements, providing assurance for the company's expansion into international markets and positively impacting the global regulatory market. The company has established a cGMP quality management system that meets global standards, enhancing its overall competitiveness"
datetime: "2025-08-12T07:41:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252618888.md)
  - [en](https://longbridge.com/en/news/252618888.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252618888.md)
---

# Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA

According to the Zhitong Finance APP, Jiuzhou Pharma (603456.SH) announced that its subsidiary, Ruibo (Suzhou) Pharmaceutical Co., Ltd. (hereinafter referred to as "Ruibo Suzhou"), underwent an inspection by the U.S. Food and Drug Administration (hereinafter referred to as "FDA") for cGMP (current Good Manufacturing Practice) from May 19 to May 22, 2025. The inspection covered six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, Ruibo Suzhou received the Establishment Inspection Report (EIR) issued by the U.S. FDA, indicating that Ruibo Suzhou has passed this cGMP inspection.

The successful completion of the U.S. FDA inspection indicates that Ruibo Suzhou meets the FDA's requirements in terms of pharmaceutical cGMP quality management systems and production environment facilities, providing a solid guarantee for the company's continuous expansion into international markets and positively impacting the expansion of the global regulated market. At the same time, the company has established a tiered cGMP quality management system that meets globally leading industry standards for research and development, production, quality control, and project management, which has a positive driving effect on enhancing the company's overall competitiveness and future development

### Related Stocks

- [603456.CN](https://longbridge.com/en/quote/603456.CN.md)

## Related News & Research

- [BoE Gov. Bailey: We have a softening picture for growth and the labour market](https://longbridge.com/en/news/287076756.md)
- [Oops! Someone Forgot To Tell Jeanine Pirro About Trump's $1.8B J6 Slush Fund](https://longbridge.com/en/news/286831031.md)
- [BoE Gov. Bailey: It is hard to put good figures on future food prices.](https://longbridge.com/en/news/287080978.md)
- [Trump is waging a silent war on legal immigration](https://longbridge.com/en/news/287081964.md)
- [15:37 ETMuse Communications Celebrates 10 Years of Award-Winning Legal Marketing and Public Relations](https://longbridge.com/en/news/286811115.md)